当前位置: 首页 > 期刊 > 《中国药房》 > 2025年第13期
编号:2390229
非霍奇金淋巴瘤患者MS4A1基因多态性与利妥昔单抗血药浓度及疗效的相关性研究
http://www.100md.com 2025年8月8日 中国药房 2025年第13期
    

    中图分类号 R969.4;R979.1 文献标志码A 文章编号 1001-0408(2025)13-1641-07

    DOI 10.6039/j.issn.1001-0408.2025.13.15

    Study on relationships of MS4A1 gene polymorphism with blood concentration and eficacy of rituximab in patientswithnon-Hodgkin'slymphoma

    SHI Feng'2,LIU Tao1,HUANG He1 ,FANG Caifu1,GUAN Shaoxing2,ZHANG Zhang1,WANG Zhao1,FANG Xiaojiel,CHEN Zhuojia’,LIU Shu'(1.Dept. of Pharmacy,Cancer Center,Sun Yat-sen University,Guangzhou 510060,China;2.School of Pharmaceutical Sciences,Sun Yat-Sen University,Guangzhou 510o06,China)

    ABSTRACTOBJECTIVETo explore the efects ofCD20 coding gene(MS4AI)polymorphismon the blood concentrationand efcacyof rituximab in patients with non-Hodgkin'slymphoma.METHODS Aprospective observational study was conductedon 160 newlydiagnosed non-Hodgkin’slymphoma patients who received theR-CHOPregimen atthe Sun Yat Sen UniversityCancer Center from January2016 toDecember 2020 ......

您现在查看是摘要页,全文长 22881 字符